UNSPSC 51422433: Hydrocortisone sodium phosphate

This classification denotes a therapeutic hydrocortisone with the molecular formula C21H29O8P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0388G963HY, chemically known as 11beta,17alpha,21-trihydroxypregn-4-ene-3,20-dione but more generally known as hydrocortisone sodium phosphate, which bears US NIH Compound Identifier 5754. European Medicines Agency schedules Hydrocortisone sodium phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02568MIG.

UNSPSC 51422433 Hydrocortisone sodium phosphate is a Commodity code for a specific corticosteroid pharmaceutical product, but the recent state and local contract opportunities posted under this code show minimal alignment with the nominal scope. The two opportunities on record — a Seminole County, Florida IFB for naloxone and drug deactivation systems, and a Texas Health and Human Services Commission RFI for direct-to-manufacturer pharmacy programs — involve pharmaceutical procurement and health-system contracting but do not reflect purchases of hydrocortisone sodium phosphate itself. State and local issuing bodies posting under this code include county health departments and state health-and-human-services agencies, suggesting that pharmaceutical commodity codes in this space are sometimes used as catch-all tags for broader pharmacy and pharmaceutical-supply procurement rather than discrete product lines.

The recent activity is geographically sparse, with identifiable opportunities in Florida and Texas only. Seminole County's IFB (solicitation IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive sealed bidding with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas HHS Commission's RFI (HHS0017013, posted April 3, 2026) was exploratory in nature, gathering vendor capabilities for a potential direct-to-manufacturer prescription program serving state employee and retiree health plans. Neither opportunity explicitly solicited hydrocortisone sodium phosphate or related corticosteroids. The code shows limited relevant recent activity, and business development professionals should verify whether this code is the appropriate vehicle for pursuing state and local pharmaceutical sales or whether opportunities in this space will cluster under broader pharmacy-benefit or drug-supply Family or Class codes instead.